About Chiesi Ventures
Chiesi Ventures is a venture capital firm founded in 2014. It is primarily based out of Boston, United States. As of Apr 2025, Chiesi Ventures has invested in 10 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across Life Sciences and High Tech sectors. Most recently it participated in the $***** Series C round of Glycomine Overall, Chiesi Ventures portfolio has seen 4 IPOs and 2 acquisitions including key companies like 4D Molecular Therapeutics, Aura Biosciences and Mirum Pharmaceuticals. A lot of funds co-invest with Chiesi Ventures, with names like Pappas Capital sharing a substantial percentage of its portfolio. Chiesi Ventures has team of 1 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A & Series B
Portfolio IPOs
Portfolio Acquisitions
Chiesi Ventures' List of Top Investments
Chiesi Ventures has a portfolio of 10 companies. Their most notable investmentis in Aura BiosciencesTheir portfolio spans across United States and Spain. They have invested in Life Sciences, High Tech, across Series A, Series B stages. Here is the list of top investments by Chiesi Ventures:4d Molecular Therapeutics researchers develop gene therapy products for severe genetic diseases involving a diverse array of target tissues, including the following areas: retina, heart, liver, brain (CNS), skeletal muscle, and lung. The company uses Directed Vector Evolution, a vector discovery platform to create customized gene delivery vehicles to deliver genes to any tissue or organ in the body.
Key facts about 4D Molecular Therapeutics
- Founded Year: 2013
- Location: Emeryville (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $187M
- Employee Count: 220 as on Jul 31, 2026
- Investors: BVF Partners, ArrowMark Partners and 18 Others
- Latest Funding Round: Series C, Jun 16, 2020, $*****
- Highlight: Public
Provider of therapies to target and destroy cancer cells. Its lead candidate is for the treatment of ocular (uveal) melanoma. It consists of a viral-like particle conjugated to an infra-red activated small molecule. It binds selectively to cancer cells in the eye and upon activation with an ophthalmic laser, the small molecule selectively destroys the membrane of cancer cells, killing them without damaging the overlying retina.
Key facts about Aura Biosciences
- Founded Year: 2007
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $215M
- Employee Count: 127 as on Jul 31, 2026
- Investors: Advent Life Sciences, Lundbeck Foundation and 20 Others
- Latest Funding Round: Series D, Mar 22, 2021, $*****
- Highlight: Public
Developer of small molecule based therapeutics to treat rare diseases. The company's lead product candidate Maralixibat inhibits a carrier protein called apical sodium-dependent bile acid transporter for reducing systemic levels of bile acids. It is used for the treatment of both Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis. The other product of the company Volixibat is used for the treatment of adult cholestasis.
Key facts about Mirum Pharmaceuticals
- Founded Year: 2018
- Location: Menlo Park (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $120M
- Employee Count: 488 as on Jul 31, 2026
- Investors: Oberland Capital, Frazier Life Sciences and 9 Others
- Latest Funding Round: Post IPO, Jan 23, 2026, $*****
- Highlight: Public
4. CuraSen
CuraSen develops drugs for neurodegenerative disorders like inflammation, proteinopathy and neuronal atrophy, Alzheimer’s, and Parkinson’s diseases. It is involved in developing small molecules and targets innate homeostatic pathways.
Key facts about CuraSen
- Founded Year: 2013
- Location: San Mateo (United States)
- Stage: Series B
- Total Funding till date: $59.8M
- Employee Count: 20 as on Jul 31, 2026
- Investors: Longitude Capital, New Leaf Venture Partners and 5 Others
- Latest Funding Round: Series B, Aug 26, 2024, $*****
- Highlight: Editors' Pick
5. Minoryx
Minoryx is a developer of therapies for rare neurometabolic diseases. It is also developing drugs for orphan diseases. The company targets inborn errors of metabolism that cause rare diseases of genetic origin. Its leading program, a PPAR gamma agonist (MIN-102) that has multiple CNS indications (phase 2/3) to treat X-ALD that is a genetic disease characterized by progressive neurologic deterioration. It is also working on non-competitive pharmacological chaperones identified through its proprietary platform Site-directed Enzyme Enhancement Therapy (SEE-Tx).
Key facts about Minoryx
- Founded Year: 2011
- Location: Mataro (Spain)
- Stage: Series D
- Total Funding till date: $107M
- Employee Count: 10 - 49 as on Mar 01, 2026
- Investors: Kurma Partners, Columbus Venture Partners and 20 Others
- Latest Funding Round: Series D, Nov 10, 2022, $*****
- Highlight: Editors' Pick
Chiesi Ventures' Year-on-Year Investment Trends
Chiesi Ventures has invested in 10 companies over the last 11 years, with an average of 1 new investment annually in the last 10 years. In 2025, it made 1 investment. Its most recent first time investment was in VelosBio and most recent follow-on round was in Glycomine.Chiesi Ventures' Investments by Stage
Chiesi Ventures has made 4 investments in Series A stage with an average round size of $26.3M and 3 investments in Series B stage with an average round size of $53.7M.Stage of entry | No. of Investments |
|---|---|
Series A | 4 |
Series B | 3 |
Note: We have considered here, only first round of investments
Chiesi Ventures' Investments by Sector
Chiesi Ventures has a diverse portfolio, with companies operating in the Life Sciences and High Tech. Notably, it has invested in 10 Tech companies and 9 Enterprise (B2B) companies.Sector | No. of Investments |
|---|---|
Life Sciences | 7 |
High Tech | 1 |
Note: We have considered here, only first round of investments
Chiesi Ventures' Investments by Geography
Chiesi Ventures has made most investments in United States (6), followed by Spain where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 6 |
Spain | 1 |
Note: We have considered here, only first round of investments
Chiesi Ventures' recent investments
Chiesi Ventures has not made any investment in 2026 so far.Here are the most recent investments by Chiesi Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 16, 2025 | United States | Series C | 9228 | ||
Jun 23, 2021 | United States | Series B | 3344 | [+7] | |
Mar 22, 2021 | United States | Series D | 3907 | ||
Jun 16, 2020 | United States | Series C | 4373 | [+14] | |
Aug 07, 2019 | United States | Series B | 1497 | [+3] |
IPOs and Publicly Listed companies in Chiesi Ventures' Portfolio
4 of Chiesi Ventures' portfolio companies have become public. Aura Biosciences got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2021 at marketcap of $398M and Reneo Pharmaceuticals got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $363M.Here are Chiesi Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 29, 2021 | Mar 05, 2015 | Series B | 4466 | |
Apr 09, 2021 | - | - | 7608 | |
Dec 11, 2020 | Sep 05, 2018 | Series B | 6532 | |
Jul 18, 2019 | - | - | 7857 |
Acquired companies in Chiesi Ventures' Portfolio
2 companies from Chiesi Ventures' portfolio have been acquired. The most recent acquisition was Kezar Life Sciences in Mar 2026 by Aurinia Pharmaceuticals for $*****.Here are Chiesi Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 30, 2026 | Jul 21, 2017 | Series B | 3050 | |
Nov 05, 2020 | Oct 01, 2018 | Series A | 9592 |
Team profile of Chiesi Ventures
Chiesi Ventures has a team of 1 member located in United States. Chiesi Ventures' team does not sit on the board of any company as of now.Co-investors of Chiesi Ventures
Over the past 11 years, 94 investors have co-invested in Chiesi Ventures's portfolio companies. This includes funds and angels.
- Invested before Chiesi Ventures: Pfizer Venture Investments, Cystic Fibrosis Foundation and 12 others have invested in rounds before Chiesi Ventures. There is 1 company where Pfizer Venture Investments has invested before Chiesi Ventures and 1 company where Cystic Fibrosis Foundation has invested before Chiesi Ventures.
- Top Co-investors of Chiesi Ventures: 30 investors entered a company along with Chiesi Ventures. These include investors like Pappas Capital (3 companies).
- Invested after Chiesi Ventures: A total of 50 investors have invested in Chiesi Ventures's portfolio after their investments. Top Investors include Columbus Venture Partners (2 companies), Matrix Capital Management (2 companies) and Citadel (2 companies).
Recent News related to Chiesi Ventures
•
Glycomine raises $115m to advance rare disease therapy into Phase IIb
Pharmaceutical Technology•Apr 16, 2025•Glycomine, CTI Life Sciences Fund, Advent Life Sciences, Novo Holdings and 7 others
•
Glycomine Secures $115M Series C Funding for Rare Disease TreatmentBioSpace•Apr 16, 2025•Glycomine, CTI Life Sciences Fund, Advent Life Sciences, Novo Holdings and 7 others
•
Glycomine Secures $115M in Series C FundingFinSMEs•Apr 16, 2025•Glycomine, CTI Life Sciences Fund, abrdn, Advent Life Sciences and 8 others
•
Glycomine Raises $68M in Series B FundingFinSMEs•Jun 25, 2021•Glycomine, Abingworth, Sanofi Ventures, RiverVest Venture Partners and 6 others
•
Aura Biosciences Announces Oversubscribed $80 Million FinancingBusiness Wire•Mar 22, 2021•Aura Biosciences, Matrix, Citadel, Rock Springs Capital and 9 others
•
4DMT goes forward with $75mGlobal Corporate Venturing•Jun 17, 2020•4D Molecular Therapeutics, Chiesi Ventures, Pfizer Venture Investments, Viking Global Investors and 2 others
•
4D Molecular Therapeutics Raises $75 Million in Series C FinancingBusiness Wire•Jun 16, 2020•4D Molecular Therapeutics, Viking Global Investors, Amzak Capital Management, Casdin Capital and 12 others
•
•
INSERTING and REPLACING Aura Biosciences Completes $40 Million Series D FinancingBusiness Wire•Apr 02, 2019•Aura Biosciences, Arix Bioscience, Medicxi, Advent Life Sciences and 5 others
•
Walmart acquires plus-sized clothing startup EloquiiReuters•Oct 02, 2018•Walmart, ELOQUII, , HEED and 23 others
